Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
Status:
Unknown status
Trial end date:
2019-05-02
Target enrollment:
Participant gender:
Summary
Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine
kinase inhibitors experience limited sites of disease progression. For multiple metastases in
patients with advanced NSCLC, increased local treatment may benefit to prolong patient
survival. This study investigated the benefits of icotinib limited systemic disease
progression and continuation of Stereotactic Body Radiation Therapy,in patients with
metastatic EGFR-mutant NSCLC.